908 Devices Inc.
908 Devices Inc. (MASS) Stock Competitors & Peer Comparison
See (MASS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MASS | $6.45 | +7.14% | 232.8M | -2.73 | -$2.36 | N/A |
| ABT | $132.59 | +0.45% | 230.8B | 16.63 | $7.97 | +1.75% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $106.17 | +0.91% | 157.3B | 63.18 | $1.68 | N/A |
| SYK | $394.22 | +2.44% | 150.7B | 52.13 | $7.56 | +0.84% |
| MDT | $92.71 | +1.77% | 118.7B | 25.60 | $3.62 | +3.03% |
| EW | $81.83 | +0.83% | 48B | 34.24 | $2.39 | N/A |
| DXCM | $82.26 | +2.03% | 32.3B | 57.93 | $1.42 | N/A |
| PHG | $28.34 | +3.28% | 26.3B | 149.13 | $0.19 | +3.13% |
| STE | $251.87 | +1.77% | 24.8B | 38.53 | $6.54 | +0.91% |
Stock Comparison
MASS vs ABT Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, ABT has a market cap of 230.8B. Regarding current trading prices, MASS is priced at $6.45, while ABT trades at $132.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas ABT's P/E ratio is 16.63. In terms of profitability, MASS's ROE is -0.13%, compared to ABT's ROE of +0.32%. Regarding short-term risk, MASS is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ABT's competition here
MASS vs BSX-PA Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, MASS is priced at $6.45, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, MASS's ROE is -0.13%, compared to BSX-PA's ROE of +0.12%. Regarding short-term risk, MASS is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check BSX-PA's competition here
MASS vs BSX Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, BSX has a market cap of 157.3B. Regarding current trading prices, MASS is priced at $6.45, while BSX trades at $106.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas BSX's P/E ratio is 63.18. In terms of profitability, MASS's ROE is -0.13%, compared to BSX's ROE of +0.12%. Regarding short-term risk, MASS is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check BSX's competition here
MASS vs SYK Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, SYK has a market cap of 150.7B. Regarding current trading prices, MASS is priced at $6.45, while SYK trades at $394.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas SYK's P/E ratio is 52.13. In terms of profitability, MASS's ROE is -0.13%, compared to SYK's ROE of +0.14%. Regarding short-term risk, MASS is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SYK's competition here
MASS vs MDT Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, MDT has a market cap of 118.7B. Regarding current trading prices, MASS is priced at $6.45, while MDT trades at $92.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas MDT's P/E ratio is 25.60. In terms of profitability, MASS's ROE is -0.13%, compared to MDT's ROE of +0.10%. Regarding short-term risk, MASS is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check MDT's competition here
MASS vs EW Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, EW has a market cap of 48B. Regarding current trading prices, MASS is priced at $6.45, while EW trades at $81.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas EW's P/E ratio is 34.24. In terms of profitability, MASS's ROE is -0.13%, compared to EW's ROE of +0.41%. Regarding short-term risk, MASS is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check EW's competition here
MASS vs DXCM Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, DXCM has a market cap of 32.3B. Regarding current trading prices, MASS is priced at $6.45, while DXCM trades at $82.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas DXCM's P/E ratio is 57.93. In terms of profitability, MASS's ROE is -0.13%, compared to DXCM's ROE of +0.26%. Regarding short-term risk, MASS is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check DXCM's competition here
MASS vs PHG Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, PHG has a market cap of 26.3B. Regarding current trading prices, MASS is priced at $6.45, while PHG trades at $28.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas PHG's P/E ratio is 149.13. In terms of profitability, MASS's ROE is -0.13%, compared to PHG's ROE of +0.01%. Regarding short-term risk, MASS is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check PHG's competition here
MASS vs STE Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, STE has a market cap of 24.8B. Regarding current trading prices, MASS is priced at $6.45, while STE trades at $251.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas STE's P/E ratio is 38.53. In terms of profitability, MASS's ROE is -0.13%, compared to STE's ROE of +0.10%. Regarding short-term risk, MASS is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check STE's competition here
MASS vs PODD Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, PODD has a market cap of 23.3B. Regarding current trading prices, MASS is priced at $6.45, while PODD trades at $330.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas PODD's P/E ratio is 101.46. In terms of profitability, MASS's ROE is -0.13%, compared to PODD's ROE of +0.18%. Regarding short-term risk, MASS is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check PODD's competition here
MASS vs ZBH Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, ZBH has a market cap of 21.3B. Regarding current trading prices, MASS is priced at $6.45, while ZBH trades at $107.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas ZBH's P/E ratio is 26.28. In terms of profitability, MASS's ROE is -0.13%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, MASS is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ZBH's competition here
MASS vs ABMD Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, MASS is priced at $6.45, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas ABMD's P/E ratio is 65.36. In terms of profitability, MASS's ROE is -0.13%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, MASS is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ABMD's competition here
MASS vs SNN Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, SNN has a market cap of 16.4B. Regarding current trading prices, MASS is priced at $6.45, while SNN trades at $37.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas SNN's P/E ratio is 33.79. In terms of profitability, MASS's ROE is -0.13%, compared to SNN's ROE of +0.09%. Regarding short-term risk, MASS is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SNN's competition here
MASS vs SWAV Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, MASS is priced at $6.45, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas SWAV's P/E ratio is 78.76. In terms of profitability, MASS's ROE is -0.13%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, MASS is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SWAV's competition here
MASS vs ALGN Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, ALGN has a market cap of 10.8B. Regarding current trading prices, MASS is priced at $6.45, while ALGN trades at $149.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas ALGN's P/E ratio is 25.25. In terms of profitability, MASS's ROE is -0.13%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, MASS is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ALGN's competition here
MASS vs PEN Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, PEN has a market cap of 10.3B. Regarding current trading prices, MASS is priced at $6.45, while PEN trades at $264.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas PEN's P/E ratio is 70.31. In terms of profitability, MASS's ROE is -0.13%, compared to PEN's ROE of +0.12%. Regarding short-term risk, MASS is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check PEN's competition here
MASS vs GMED Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, GMED has a market cap of 8.4B. Regarding current trading prices, MASS is priced at $6.45, while GMED trades at $62.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas GMED's P/E ratio is 24.24. In terms of profitability, MASS's ROE is -0.13%, compared to GMED's ROE of +0.09%. Regarding short-term risk, MASS is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check GMED's competition here
MASS vs BIO Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, BIO has a market cap of 8.2B. Regarding current trading prices, MASS is priced at $6.45, while BIO trades at $303.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas BIO's P/E ratio is 27.41. In terms of profitability, MASS's ROE is -0.13%, compared to BIO's ROE of +0.05%. Regarding short-term risk, MASS is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check BIO's competition here
MASS vs BIO-B Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, BIO-B has a market cap of 6.7B. Regarding current trading prices, MASS is priced at $6.45, while BIO-B trades at $247.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas BIO-B's P/E ratio is -3.23. In terms of profitability, MASS's ROE is -0.13%, compared to BIO-B's ROE of +0.05%. Regarding short-term risk, MASS is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check BIO-B's competition here
MASS vs IRTC Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, IRTC has a market cap of 5.4B. Regarding current trading prices, MASS is priced at $6.45, while IRTC trades at $169.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas IRTC's P/E ratio is -57.92. In terms of profitability, MASS's ROE is -0.13%, compared to IRTC's ROE of -1.05%. Regarding short-term risk, MASS is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check IRTC's competition here
MASS vs GKOS Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, GKOS has a market cap of 5.4B. Regarding current trading prices, MASS is priced at $6.45, while GKOS trades at $94.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas GKOS's P/E ratio is -58.49. In terms of profitability, MASS's ROE is -0.13%, compared to GKOS's ROE of -0.13%. Regarding short-term risk, MASS is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check GKOS's competition here
MASS vs BRKR Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, BRKR has a market cap of 5.4B. Regarding current trading prices, MASS is priced at $6.45, while BRKR trades at $35.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas BRKR's P/E ratio is 68.35. In terms of profitability, MASS's ROE is -0.13%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, MASS is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check BRKR's competition here
MASS vs NARI Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, MASS is priced at $6.45, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas NARI's P/E ratio is -59.24. In terms of profitability, MASS's ROE is -0.13%, compared to NARI's ROE of -0.17%. Regarding short-term risk, MASS is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check NARI's competition here
MASS vs TMDX Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, TMDX has a market cap of 4.1B. Regarding current trading prices, MASS is priced at $6.45, while TMDX trades at $119.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas TMDX's P/E ratio is 60.23. In terms of profitability, MASS's ROE is -0.13%, compared to TMDX's ROE of +0.28%. Regarding short-term risk, MASS is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check TMDX's competition here
MASS vs ITGR Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, ITGR has a market cap of 3.9B. Regarding current trading prices, MASS is priced at $6.45, while ITGR trades at $110.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas ITGR's P/E ratio is 47.30. In terms of profitability, MASS's ROE is -0.13%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, MASS is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ITGR's competition here
MASS vs AXNX Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, MASS is priced at $6.45, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas AXNX's P/E ratio is -709.80. In terms of profitability, MASS's ROE is -0.13%, compared to AXNX's ROE of -0.02%. Regarding short-term risk, MASS is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check AXNX's competition here
MASS vs LIVN Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, LIVN has a market cap of 3.1B. Regarding current trading prices, MASS is priced at $6.45, while LIVN trades at $55.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas LIVN's P/E ratio is -14.41. In terms of profitability, MASS's ROE is -0.13%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, MASS is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check LIVN's competition here
MASS vs INSP Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, INSP has a market cap of 2.8B. Regarding current trading prices, MASS is priced at $6.45, while INSP trades at $95.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas INSP's P/E ratio is 55.21. In terms of profitability, MASS's ROE is -0.13%, compared to INSP's ROE of +0.08%. Regarding short-term risk, MASS is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check INSP's competition here
MASS vs ATEC Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, ATEC has a market cap of 2.4B. Regarding current trading prices, MASS is priced at $6.45, while ATEC trades at $16.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas ATEC's P/E ratio is -14.28. In terms of profitability, MASS's ROE is -0.13%, compared to ATEC's ROE of -2.52%. Regarding short-term risk, MASS is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ATEC's competition here
MASS vs PRCT Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, PRCT has a market cap of 2.3B. Regarding current trading prices, MASS is priced at $6.45, while PRCT trades at $41.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas PRCT's P/E ratio is -26.77. In terms of profitability, MASS's ROE is -0.13%, compared to PRCT's ROE of -0.24%. Regarding short-term risk, MASS is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check PRCT's competition here
MASS vs AORT Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, AORT has a market cap of 2.1B. Regarding current trading prices, MASS is priced at $6.45, while AORT trades at $44.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas AORT's P/E ratio is -104.26. In terms of profitability, MASS's ROE is -0.13%, compared to AORT's ROE of -0.06%. Regarding short-term risk, MASS is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check AORT's competition here
MASS vs NUVA Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, MASS is priced at $6.45, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas NUVA's P/E ratio is 75.00. In terms of profitability, MASS's ROE is -0.13%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, MASS is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check NUVA's competition here
MASS vs UFPT Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, MASS is priced at $6.45, while UFPT trades at $225.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas UFPT's P/E ratio is 26.16. In terms of profitability, MASS's ROE is -0.13%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, MASS is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check UFPT's competition here
MASS vs CNMD Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, CNMD has a market cap of 1.7B. Regarding current trading prices, MASS is priced at $6.45, while CNMD trades at $55.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas CNMD's P/E ratio is 15.77. In terms of profitability, MASS's ROE is -0.13%, compared to CNMD's ROE of +0.11%. Regarding short-term risk, MASS is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check CNMD's competition here
MASS vs SSII Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, SSII has a market cap of 1.4B. Regarding current trading prices, MASS is priced at $6.45, while SSII trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas SSII's P/E ratio is -116.50. In terms of profitability, MASS's ROE is -0.13%, compared to SSII's ROE of -0.71%. Regarding short-term risk, MASS is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check SSII's competition here
MASS vs HSKA Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, MASS is priced at $6.45, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas HSKA's P/E ratio is -62.49. In terms of profitability, MASS's ROE is -0.13%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, MASS is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check HSKA's competition here
MASS vs AHCO Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, MASS is priced at $6.45, while AHCO trades at $9.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas AHCO's P/E ratio is 17.79. In terms of profitability, MASS's ROE is -0.13%, compared to AHCO's ROE of +0.05%. Regarding short-term risk, MASS is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check AHCO's competition here
MASS vs ESTA Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, ESTA has a market cap of 1.3B. Regarding current trading prices, MASS is priced at $6.45, while ESTA trades at $43.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas ESTA's P/E ratio is -14.17. In terms of profitability, MASS's ROE is -0.13%, compared to ESTA's ROE of -2.41%. Regarding short-term risk, MASS is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check ESTA's competition here
MASS vs IART Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, IART has a market cap of 1.2B. Regarding current trading prices, MASS is priced at $6.45, while IART trades at $14.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas IART's P/E ratio is -2.27. In terms of profitability, MASS's ROE is -0.13%, compared to IART's ROE of -0.36%. Regarding short-term risk, MASS is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check IART's competition here
MASS vs SILK Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, MASS is priced at $6.45, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas SILK's P/E ratio is -18.96. In terms of profitability, MASS's ROE is -0.13%, compared to SILK's ROE of -0.20%. Regarding short-term risk, MASS is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SILK's competition here
MASS vs FNA Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, MASS is priced at $6.45, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas FNA's P/E ratio is -19.83. In terms of profitability, MASS's ROE is -0.13%, compared to FNA's ROE of -0.36%. Regarding short-term risk, MASS is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check FNA's competition here
MASS vs INMD Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, INMD has a market cap of 1B. Regarding current trading prices, MASS is priced at $6.45, while INMD trades at $14.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas INMD's P/E ratio is 6.22. In terms of profitability, MASS's ROE is -0.13%, compared to INMD's ROE of +0.27%. Regarding short-term risk, MASS is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check INMD's competition here
MASS vs IRMD Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, IRMD has a market cap of 924.2M. Regarding current trading prices, MASS is priced at $6.45, while IRMD trades at $72.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas IRMD's P/E ratio is 45.13. In terms of profitability, MASS's ROE is -0.13%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, MASS is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check IRMD's competition here
MASS vs CSII Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, MASS is priced at $6.45, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas CSII's P/E ratio is -20.83. In terms of profitability, MASS's ROE is -0.13%, compared to CSII's ROE of -0.14%. Regarding short-term risk, MASS is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check CSII's competition here
MASS vs TNDM Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, TNDM has a market cap of 806.1M. Regarding current trading prices, MASS is priced at $6.45, while TNDM trades at $11.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas TNDM's P/E ratio is -3.87. In terms of profitability, MASS's ROE is -0.13%, compared to TNDM's ROE of -1.04%. Regarding short-term risk, MASS is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check TNDM's competition here
MASS vs AXGN Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, AXGN has a market cap of 748.2M. Regarding current trading prices, MASS is priced at $6.45, while AXGN trades at $16.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas AXGN's P/E ratio is -162.60. In terms of profitability, MASS's ROE is -0.13%, compared to AXGN's ROE of -0.04%. Regarding short-term risk, MASS is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check AXGN's competition here
MASS vs CRY Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, MASS is priced at $6.45, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas CRY's P/E ratio is 425.71. In terms of profitability, MASS's ROE is -0.13%, compared to CRY's ROE of -0.05%. Regarding short-term risk, MASS is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check CRY's competition here
MASS vs SIBN Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, SIBN has a market cap of 707.1M. Regarding current trading prices, MASS is priced at $6.45, while SIBN trades at $16.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas SIBN's P/E ratio is -28.75. In terms of profitability, MASS's ROE is -0.13%, compared to SIBN's ROE of -0.14%. Regarding short-term risk, MASS is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SIBN's competition here
MASS vs APEN Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, MASS is priced at $6.45, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas APEN's P/E ratio is -9.43. In terms of profitability, MASS's ROE is -0.13%, compared to APEN's ROE of -0.85%. Regarding short-term risk, MASS is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check APEN's competition here
MASS vs OFIX Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, OFIX has a market cap of 574.6M. Regarding current trading prices, MASS is priced at $6.45, while OFIX trades at $14.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas OFIX's P/E ratio is -4.59. In terms of profitability, MASS's ROE is -0.13%, compared to OFIX's ROE of -0.25%. Regarding short-term risk, MASS is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check OFIX's competition here
MASS vs AVNS Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, AVNS has a market cap of 542.9M. Regarding current trading prices, MASS is priced at $6.45, while AVNS trades at $11.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas AVNS's P/E ratio is -1.17. In terms of profitability, MASS's ROE is -0.13%, compared to AVNS's ROE of -0.50%. Regarding short-term risk, MASS is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check AVNS's competition here
MASS vs ZIMV Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, ZIMV has a market cap of 534.4M. Regarding current trading prices, MASS is priced at $6.45, while ZIMV trades at $18.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas ZIMV's P/E ratio is -27.46. In terms of profitability, MASS's ROE is -0.13%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, MASS is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ZIMV's competition here
MASS vs SRDX Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, SRDX has a market cap of 531.7M. Regarding current trading prices, MASS is priced at $6.45, while SRDX trades at $37.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas SRDX's P/E ratio is -29.99. In terms of profitability, MASS's ROE is -0.13%, compared to SRDX's ROE of -0.16%. Regarding short-term risk, MASS is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SRDX's competition here
MASS vs CTKB Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, CTKB has a market cap of 528M. Regarding current trading prices, MASS is priced at $6.45, while CTKB trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas CTKB's P/E ratio is -83.00. In terms of profitability, MASS's ROE is -0.13%, compared to CTKB's ROE of -0.02%. Regarding short-term risk, MASS is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check CTKB's competition here
MASS vs BVS Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, BVS has a market cap of 511.1M. Regarding current trading prices, MASS is priced at $6.45, while BVS trades at $7.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas BVS's P/E ratio is 254.67. In terms of profitability, MASS's ROE is -0.13%, compared to BVS's ROE of -0.00%. Regarding short-term risk, MASS is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check BVS's competition here
MASS vs KIDS Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, KIDS has a market cap of 506.5M. Regarding current trading prices, MASS is priced at $6.45, while KIDS trades at $20.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas KIDS's P/E ratio is -11.22. In terms of profitability, MASS's ROE is -0.13%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, MASS is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check KIDS's competition here
MASS vs TMCI Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, TMCI has a market cap of 486.4M. Regarding current trading prices, MASS is priced at $6.45, while TMCI trades at $7.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas TMCI's P/E ratio is -9.75. In terms of profitability, MASS's ROE is -0.13%, compared to TMCI's ROE of -0.47%. Regarding short-term risk, MASS is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check TMCI's competition here
MASS vs VREX Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, VREX has a market cap of 482.2M. Regarding current trading prices, MASS is priced at $6.45, while VREX trades at $11.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas VREX's P/E ratio is -3.60. In terms of profitability, MASS's ROE is -0.13%, compared to VREX's ROE of -0.25%. Regarding short-term risk, MASS is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check VREX's competition here
MASS vs SMLR Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, SMLR has a market cap of 465.3M. Regarding current trading prices, MASS is priced at $6.45, while SMLR trades at $31.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas SMLR's P/E ratio is 6.89. In terms of profitability, MASS's ROE is -0.13%, compared to SMLR's ROE of +0.17%. Regarding short-term risk, MASS is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SMLR's competition here
MASS vs CBLL Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, CBLL has a market cap of 442.2M. Regarding current trading prices, MASS is priced at $6.45, while CBLL trades at $12.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas CBLL's P/E ratio is -3.34. In terms of profitability, MASS's ROE is -0.13%, compared to CBLL's ROE of -0.48%. Regarding short-term risk, MASS is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check CBLL's competition here
MASS vs PACB Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, PACB has a market cap of 414.5M. Regarding current trading prices, MASS is priced at $6.45, while PACB trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas PACB's P/E ratio is -0.62. In terms of profitability, MASS's ROE is -0.13%, compared to PACB's ROE of -1.89%. Regarding short-term risk, MASS is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check PACB's competition here
MASS vs SNWV Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, SNWV has a market cap of 385.6M. Regarding current trading prices, MASS is priced at $6.45, while SNWV trades at $45.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas SNWV's P/E ratio is -5.47. In terms of profitability, MASS's ROE is -0.13%, compared to SNWV's ROE of +1.45%. Regarding short-term risk, MASS is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check SNWV's competition here
MASS vs BFLY Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, BFLY has a market cap of 382.6M. Regarding current trading prices, MASS is priced at $6.45, while BFLY trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas BFLY's P/E ratio is -5.43. In terms of profitability, MASS's ROE is -0.13%, compared to BFLY's ROE of -0.31%. Regarding short-term risk, MASS is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check BFLY's competition here
MASS vs RXST Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, RXST has a market cap of 379.7M. Regarding current trading prices, MASS is priced at $6.45, while RXST trades at $9.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas RXST's P/E ratio is -11.60. In terms of profitability, MASS's ROE is -0.13%, compared to RXST's ROE of -0.12%. Regarding short-term risk, MASS is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check RXST's competition here
MASS vs SENS Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, SENS has a market cap of 375.6M. Regarding current trading prices, MASS is priced at $6.45, while SENS trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas SENS's P/E ratio is -4.61. In terms of profitability, MASS's ROE is -0.13%, compared to SENS's ROE of -12.27%. Regarding short-term risk, MASS is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check SENS's competition here
MASS vs BFLY-WT Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, BFLY-WT has a market cap of 362.7M. Regarding current trading prices, MASS is priced at $6.45, while BFLY-WT trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, MASS's ROE is -0.13%, compared to BFLY-WT's ROE of -0.31%. Regarding short-term risk, MASS is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check BFLY-WT's competition here
MASS vs CLPT Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, CLPT has a market cap of 304.2M. Regarding current trading prices, MASS is priced at $6.45, while CLPT trades at $10.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas CLPT's P/E ratio is -13.37. In terms of profitability, MASS's ROE is -0.13%, compared to CLPT's ROE of -0.94%. Regarding short-term risk, MASS is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check CLPT's competition here
MASS vs NPCE Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, NPCE has a market cap of 297.4M. Regarding current trading prices, MASS is priced at $6.45, while NPCE trades at $8.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas NPCE's P/E ratio is -10.96. In terms of profitability, MASS's ROE is -0.13%, compared to NPCE's ROE of -1.12%. Regarding short-term risk, MASS is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check NPCE's competition here
MASS vs TCMD Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, TCMD has a market cap of 294.9M. Regarding current trading prices, MASS is priced at $6.45, while TCMD trades at $13.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas TCMD's P/E ratio is 21.34. In terms of profitability, MASS's ROE is -0.13%, compared to TCMD's ROE of +0.07%. Regarding short-term risk, MASS is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check TCMD's competition here
MASS vs BWAY Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, BWAY has a market cap of 287.3M. Regarding current trading prices, MASS is priced at $6.45, while BWAY trades at $15.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas BWAY's P/E ratio is 54.29. In terms of profitability, MASS's ROE is -0.13%, compared to BWAY's ROE of +0.09%. Regarding short-term risk, MASS is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check BWAY's competition here
MASS vs VMD Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, VMD has a market cap of 283.5M. Regarding current trading prices, MASS is priced at $6.45, while VMD trades at $7.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas VMD's P/E ratio is 21.50. In terms of profitability, MASS's ROE is -0.13%, compared to VMD's ROE of +0.11%. Regarding short-term risk, MASS is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check VMD's competition here
MASS vs CATX Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, CATX has a market cap of 272.9M. Regarding current trading prices, MASS is priced at $6.45, while CATX trades at $3.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas CATX's P/E ratio is -2.68. In terms of profitability, MASS's ROE is -0.13%, compared to CATX's ROE of -0.32%. Regarding short-term risk, MASS is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check CATX's competition here
MASS vs NNOX Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, NNOX has a market cap of 258.9M. Regarding current trading prices, MASS is priced at $6.45, while NNOX trades at $4.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas NNOX's P/E ratio is -4.51. In terms of profitability, MASS's ROE is -0.13%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, MASS is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check NNOX's competition here
MASS vs OM Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, OM has a market cap of 252.3M. Regarding current trading prices, MASS is priced at $6.45, while OM trades at $14.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas OM's P/E ratio is -0.76. In terms of profitability, MASS's ROE is -0.13%, compared to OM's ROE of -0.98%. Regarding short-term risk, MASS is more volatile compared to OM. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check OM's competition here
MASS vs CERS Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, CERS has a market cap of 242.5M. Regarding current trading prices, MASS is priced at $6.45, while CERS trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas CERS's P/E ratio is -12.65. In terms of profitability, MASS's ROE is -0.13%, compared to CERS's ROE of -0.34%. Regarding short-term risk, MASS is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check CERS's competition here
MASS vs QTRX Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, QTRX has a market cap of 224.4M. Regarding current trading prices, MASS is priced at $6.45, while QTRX trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas QTRX's P/E ratio is -2.67. In terms of profitability, MASS's ROE is -0.13%, compared to QTRX's ROE of -0.22%. Regarding short-term risk, MASS is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check QTRX's competition here
MASS vs NVRO Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, MASS is priced at $6.45, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas NVRO's P/E ratio is -1.91. In terms of profitability, MASS's ROE is -0.13%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, MASS is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check NVRO's competition here
MASS vs SGHT Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, SGHT has a market cap of 221.5M. Regarding current trading prices, MASS is priced at $6.45, while SGHT trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas SGHT's P/E ratio is -4.41. In terms of profitability, MASS's ROE is -0.13%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, MASS is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SGHT's competition here
MASS vs EYES Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, MASS is priced at $6.45, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas EYES's P/E ratio is N/A. In terms of profitability, MASS's ROE is -0.13%, compared to EYES's ROE of -0.26%. Regarding short-term risk, MASS is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check EYES's competition here
MASS vs INGN Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, INGN has a market cap of 209.6M. Regarding current trading prices, MASS is priced at $6.45, while INGN trades at $7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas INGN's P/E ratio is -7.31. In terms of profitability, MASS's ROE is -0.13%, compared to INGN's ROE of -0.14%. Regarding short-term risk, MASS is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check INGN's competition here
MASS vs CVRX Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, CVRX has a market cap of 204M. Regarding current trading prices, MASS is priced at $6.45, while CVRX trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas CVRX's P/E ratio is -3.79. In terms of profitability, MASS's ROE is -0.13%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, MASS is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check CVRX's competition here
MASS vs MGRM Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, MGRM has a market cap of 197.1M. Regarding current trading prices, MASS is priced at $6.45, while MGRM trades at $5.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas MGRM's P/E ratio is -10.09. In terms of profitability, MASS's ROE is -0.13%, compared to MGRM's ROE of -1.37%. Regarding short-term risk, MASS is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check MGRM's competition here
MASS vs TLSI Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, TLSI has a market cap of 191.8M. Regarding current trading prices, MASS is priced at $6.45, while TLSI trades at $5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas TLSI's P/E ratio is -4.39. In terms of profitability, MASS's ROE is -0.13%, compared to TLSI's ROE of +1.27%. Regarding short-term risk, MASS is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check TLSI's competition here
MASS vs ELMD Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, ELMD has a market cap of 169.1M. Regarding current trading prices, MASS is priced at $6.45, while ELMD trades at $20.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas ELMD's P/E ratio is 25.53. In terms of profitability, MASS's ROE is -0.13%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, MASS is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ELMD's competition here
MASS vs BSGM Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, BSGM has a market cap of 162.3M. Regarding current trading prices, MASS is priced at $6.45, while BSGM trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas BSGM's P/E ratio is -4.93. In terms of profitability, MASS's ROE is -0.13%, compared to BSGM's ROE of +41.24%. Regarding short-term risk, MASS is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check BSGM's competition here
MASS vs LNSR Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, LNSR has a market cap of 154M. Regarding current trading prices, MASS is priced at $6.45, while LNSR trades at $12.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas LNSR's P/E ratio is -3.06. In terms of profitability, MASS's ROE is -0.13%, compared to LNSR's ROE of +51.79%. Regarding short-term risk, MASS is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check LNSR's competition here
MASS vs MXCT Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, MXCT has a market cap of 151.4M. Regarding current trading prices, MASS is priced at $6.45, while MXCT trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas MXCT's P/E ratio is -3.38. In terms of profitability, MASS's ROE is -0.13%, compared to MXCT's ROE of -0.22%. Regarding short-term risk, MASS is more volatile compared to MXCT. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check MXCT's competition here
MASS vs AVR Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, AVR has a market cap of 149.3M. Regarding current trading prices, MASS is priced at $6.45, while AVR trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas AVR's P/E ratio is -1.36. In terms of profitability, MASS's ROE is -0.13%, compared to AVR's ROE of -2.52%. Regarding short-term risk, MASS is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check AVR's competition here
MASS vs PROF Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, PROF has a market cap of 142.5M. Regarding current trading prices, MASS is priced at $6.45, while PROF trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas PROF's P/E ratio is -3.27. In terms of profitability, MASS's ROE is -0.13%, compared to PROF's ROE of -0.91%. Regarding short-term risk, MASS is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check PROF's competition here
MASS vs ANIK Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, ANIK has a market cap of 139.1M. Regarding current trading prices, MASS is priced at $6.45, while ANIK trades at $9.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas ANIK's P/E ratio is -10.72. In terms of profitability, MASS's ROE is -0.13%, compared to ANIK's ROE of -0.38%. Regarding short-term risk, MASS is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ANIK's competition here
MASS vs RCEL Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, RCEL has a market cap of 130M. Regarding current trading prices, MASS is priced at $6.45, while RCEL trades at $4.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas RCEL's P/E ratio is -2.48. In terms of profitability, MASS's ROE is -0.13%, compared to RCEL's ROE of +279.91%. Regarding short-term risk, MASS is more volatile compared to RCEL. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check RCEL's competition here
MASS vs OWLT Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, OWLT has a market cap of 128.9M. Regarding current trading prices, MASS is priced at $6.45, while OWLT trades at $7.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas OWLT's P/E ratio is -2.02. In terms of profitability, MASS's ROE is -0.13%, compared to OWLT's ROE of +2.12%. Regarding short-term risk, MASS is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check OWLT's competition here
MASS vs RPID Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, RPID has a market cap of 125.5M. Regarding current trading prices, MASS is priced at $6.45, while RPID trades at $2.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas RPID's P/E ratio is -2.85. In terms of profitability, MASS's ROE is -0.13%, compared to RPID's ROE of -0.63%. Regarding short-term risk, MASS is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check RPID's competition here
MASS vs LUCD Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, LUCD has a market cap of 119.3M. Regarding current trading prices, MASS is priced at $6.45, while LUCD trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas LUCD's P/E ratio is -1.16. In terms of profitability, MASS's ROE is -0.13%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, MASS is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check LUCD's competition here
MASS vs ICAD Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, MASS is priced at $6.45, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas ICAD's P/E ratio is -20.37. In terms of profitability, MASS's ROE is -0.13%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, MASS is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ICAD's competition here
MASS vs HYPR Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, HYPR has a market cap of 101.8M. Regarding current trading prices, MASS is priced at $6.45, while HYPR trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas HYPR's P/E ratio is -2.49. In terms of profitability, MASS's ROE is -0.13%, compared to HYPR's ROE of -0.85%. Regarding short-term risk, MASS is more volatile compared to HYPR. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check HYPR's competition here
MASS vs NSPR Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, NSPR has a market cap of 99.1M. Regarding current trading prices, MASS is priced at $6.45, while NSPR trades at $2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas NSPR's P/E ratio is -2.93. In terms of profitability, MASS's ROE is -0.13%, compared to NSPR's ROE of -1.31%. Regarding short-term risk, MASS is more volatile compared to NSPR. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check NSPR's competition here
MASS vs HJLI Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, MASS is priced at $6.45, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas HJLI's P/E ratio is N/A. In terms of profitability, MASS's ROE is -0.13%, compared to HJLI's ROE of -0.00%. Regarding short-term risk, MASS is more volatile compared to HJLI. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check HJLI's competition here
MASS vs ASXC Comparison August 2025
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 232.8M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, MASS is priced at $6.45, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -2.73, whereas ASXC's P/E ratio is -1.12. In terms of profitability, MASS's ROE is -0.13%, compared to ASXC's ROE of -56.86%. Regarding short-term risk, MASS is more volatile compared to ASXC. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ASXC's competition here